Maya Martinez-Davis
Corporate Officer/Principal en GSK PLC .
Perfil
Maya Martinez-Davis is currently the President-US Pharmaceuticals at GSK Plc.
Prior to this, she was the Independent Director at Mirati Therapeutics, Inc. from 2018 to 2024 and the President-Biopharma Latin America at Merck KGaA from 2016 to 2019.
She completed her undergraduate degree at St. Louis University and her graduate degree at Instituto de Empresa SL.
Cargos activos de Maya Martinez-Davis
| Empresas | Cargo | Inicio |
|---|---|---|
| GSK PLC | Corporate Officer/Principal | 01/01/2020 |
Antiguos cargos conocidos de Maya Martinez-Davis.
| Empresas | Cargo | Fin |
|---|---|---|
| MIRATI THERAPEUTICS | Director/Board Member | 23/01/2024 |
| MERCK KGAA | Corporate Officer/Principal | 01/08/2019 |
Formación de Maya Martinez-Davis.
| St. Louis University | Undergraduate Degree |
| Instituto de Empresa SL | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| MERCK KGAA | Health Technology |
| GSK PLC | Health Technology |
| Empresas privadas | 1 |
|---|---|
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Maya Martinez-Davis
